In the United States, antitrust enforcement authorities and private litigation in the pharmaceutical sector have in the past few years focused on the antitrust implications of brand-name pharmaceutical life-cycle management strategies, in general, and agreements between branded and generic drugs in settling patent litigation, in particular. We anticipate this focus will continue for the next few years as litigation on these issues makes its way through the US courts. We also anticipate a continued focus on legislation regarding these issues, particularly in light of continued US appellate court and district court rejection of the legal standard advocated by the Federal Trade Commission (FTC) in this field.